AVDL Live signaler | Maksimer profitt med Getagraph.com

SELG 109757 min ago

@ $14.22

Utstedt: 14 feb 2024 @ 15:32

Avkastning: 28.62%

Forrige signal: feb 13 - 15:30

Forrige signal: Kjøp

Avkastning: -0.21 %

Live Chart Being Loaded With Signals

Commentary (30 apr 2024 @ 21:50):

Stats
Dagens volum	618 486
Gjennomsnittsvolum	1.19M
Markedsverdi	1.85B
EPS	$0 ( 2024-03-04 )
Neste inntjeningsdato	( $-0.250 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.14
ATR14	$0.0180 (0.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-20	Kim Richard J	Buy	147 000	Stock Option (Right to Buy)
2024-02-20	Mchugh Thomas S	Buy	157 500	Stock Option (Right to Buy)
2024-02-20	Divis Gregory J	Buy	600 000	Stock Option (Right to Buy)
2024-01-16	Mchugh Thomas S	Buy	2 000	ADSs
2023-12-28	Mccamish Mark Anthony	Sell	75 000	ADSs

INSIDER POWER
81.01
Last 94 transactions
Buy: 6 417 800 \| Sell: 317 647

Volum Korrelasjon

Lang: -0.06 (neutral)

Kort: 0.72 (moderate)

Signal:(49.749) Neutral

Avadel Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
HSKA	0.968
ATRS	0.958
LIQT	0.946
ISEE	0.944
XLRN	0.94
BLU	0.936
OVID	0.934
CFIV	0.933
MNST	0.93
LABP	0.93

10 Mest negative korrelasjoner
PEAR	-0.951
MTEX	-0.946
VYNT	-0.944
NTGR	-0.939
CFBK	-0.937
HMST	-0.931
VORB	-0.93
INFN	-0.929
AUB	-0.927
EVBG	-0.925

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Avadel Pharmaceuticals Korrelasjon - Valuta/Råvare

-0.46
( neutral )

-0.41
( neutral )

0.28
( neutral )

-0.35
( neutral )

-0.34
( neutral )

0.13
( neutral )

Avadel Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$27.96M
Bruttogevinst:	$25.35M (90.66 %)
EPS:	$-2.00

FY	2023
Omsetning:	$27.96M
Bruttogevinst:	$25.35M (90.66 %)
EPS:	$-2.00

FY	2022
Omsetning:	$0
Bruttogevinst:	$-1.49M (0.00 %)
EPS:	$-2.29

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.320

Financial Reports:

No articles found.

Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Sanntidsoppdatering for Avadel Pharmaceuticals [AVDL]

Upcoming Earnings Alert